- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02818699
Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is being conducted to assess the effect of supplementation with Enzymatically Modified Isoquercitrin (EMIQ) vs. placebo on measures of total body fat in overweight and obese adults. Participants will visit the HNRCA on 5 different dates.
Visit 1: Participants will receive materials and instruction for completing 24-hour dietary recalls to be completed by phone a week prior to the next visit.
Visit 2: Overnight fasted participants will arrive to the Human Nutrition Research Center on Aging (HNRCA). Vital signs, and EKG measure of heart rhythm, scrub weight and height will be obtained. Blood samples will be collected. Several baseline measurements will be performed during this visit including: lipid profile, insulin test, adiponectin, a urine dip stick, skinfold thickness and waist/hip circumference, resting metabolic rate (RMR), and DXA measure of total body fat. A three factor eating questionnaire, food craving questionnaire, and the Stanford 7-Day Physical Activity Recall (PAR) will be administered to assess volunteer's dietary inhibition, restraint, hunger, cravings and physical activity level. EMIQ and placebo capsules, compliance calendar, and instructions will be dispensed to participants by nursing staff.
Visit 3: Overnight fasted participants will arrive to HNRCA four weeks from the last visit. Participants will be asked to return their unused supplements as well as their compliance calendar. Vital signs, scrub weight and changes to volunteer health, medication and eligibility status will be assessed. Blood samples will be collected. A second EKG will be performed. The PAR will be administered. Before their next visit, participants will complete 3 24- hour dietary recalls by phone.
Visit 4: overnight fasted participants will arrive to HNRCA four weeks from the last visit. Participants will be asked to return their unused supplements as well as their compliance calendar. Vital signs, scrub weight and changes to volunteer health, medication and eligibility status will be assessed. Blood samples will be collected. The PAR will be administered. Before their next visit, participants will complete 3 24- hour dietary recalls by phone.
Visit 5: Overnight fasted participants will arrive to HNRCA four weeks from the last visit. Vital signs and scrub weight will be assessed. Blood samples will be collected. Final measurements will be taken during this visit including: routine health screening analysis, lipid profile, adiponectin, insulin test, a urine dip stick, liver and kidney function (SGOT, SGPT, BUN, creatinine, and calculated GFR), skin fold thickness, DXA, RMR and waist/hip circumference. A three factor eating questionnaire, food craving questionnaire, and the PAR will be administered to assess changes in volunteer's dietary inhibition, restraint, hunger, cravings and activity level throughout the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Human Nutrition Research Center on Aging at Tufts University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female age 18-65 years.
- Premenopausal female with regular menstrual cycle or post-menopausal female with cessation of menstrual cycle for a minimum of 6 months.
- BMI in the range of 28.0-35.0
- Beck Depression Inventory Score less than 20.
- Fluency in spoken or written English.
- Willingness to be randomized to take EMIQ or placebo.
- Must weigh at least 164lbs
Exclusion Criteria:
- Any major illness or condition that may interfere with study outcomes at the discretion of the study physician.
- Diabetes Type I & Type II, or use of any pharmacological treatment for diabetes.
- Use of medications that interfere with energy metabolism
- Receiving hormone therapy growth hormone, testosterone, or estrogen with the exception of hormone contraceptives.
- GI diseases, conditions or medications known to influence GI absorption including active peptic ulcer disease or inflammatory bowel disease such as ulcerative colitis, Crohn's disease, celiac disease, chronic diarrhea or constipation.
- Undergone gastric bypass or other bariatric weight loss procedure.
- Lipid lowering medications such as: bile acid sequestrants (Cholestyramine, Colestipol, Colesevelam, etc.), cholesterol absorption inhibitors (Ezetimibe-Zetia), and fibrates (Gemfibrozil, Clofibrate, Fenofibrate, Triclor). Exceptions to this exclusion are 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase or Statins).
- On or planning to participate in a weight loss program.
- Weight loss or weight gain greater than 10 lbs in the past 6 months.
- History of eating disorders, anorexia, bulimia, or binge-eating in the past 5 years.
- Participation in any regular endurance exercise: running, biking or aerobics (except walking) greater than 2.5 hours per week, or resistance training greater than once per week.
- Regular use of acid lowering medications (greater than 3 times per week) such as antacids, proton pump inhibitors (PPIs), or H2 blockers.
- Unstable thyroid disease.
- Psychiatric disorders including schizophrenia, bipolar, major depression or psychosis.
- Antidepressant medication: selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase (MAO) inhibitors, or tricyclic antidepressants (TCAs).
- Cancer of any type (except for non-melanoma skin) in the past 5 years.
- Use of chemotherapeutic agents.
- Pregnancy, planning to become pregnant during the study period, or breastfeeding.
- Unwilling to use effective birth control during study.
- History of bilateral mastectomy with nodal dissection.
- Alcohol use, on average, greater than 3 servings per day, 20 servings per week (Serving size: 12oz beer, 4oz wine, 2oz hard liquor), or self-reported binge drinking.
- Uncontrolled hypertension (HTN) determined at the discretion of the study MD or registered nurse (RN). HTN medications allowed in the study: angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, and diuretics.
- Medications for chronic obstructive pulmonary disease (COPD) or kidney disease.
- α-adrenergic or β-adrenergic blockers (oral or ocular) and diuretics.
- Renal or chronic kidney disease due to any condition, renovascular disease, or dialysis.
- Chronic liver disease such as hepatitis B, hepatitis C, or cirrhosis.
- Cardiovascular disease including: myocardial infarction, cerebrovascular disease (CVA), coronary artery bypass graft, stenosis greater than 50%, angina, coronary artery disease (CAD), congestive heart failure (CHF),peripheral vascular disease (PVD) or dysautonomia.
- History of autoimmune diseases such as rheumatoid arthritis, lupus, multiple sclerosis, vitiligo, or psoriasis.
- HIV or AIDS based on self-report.
- Steroid use with the exception of over-the-counter topical and nasal steroids such as Flonase.
- Allergy medication or regular antihistamine use.
- Seizure disorders. Acceptable if managed with medication and free of seizure activity for 5 years.
- Smoking or the use of nicotine replacement products in the past 6 months.
- Use of dietary supplements containing vitamins (except Calcium and Vitamin D), minerals, herbal or plant-based preparations, fish oil or homeopathic remedies during study participation unless willing to discontinue prior to enrollment.
- Current participation in another research study.
- Non-English speaking.
- No social security number.
- Participation in another research study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo Capsule
Participants assigned to this group will receive placebo capsules identical in appearance to EMIQ capsules.
|
280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
|
EXPERIMENTAL: EMIQ Capsule
Participants assigned to this group will receive EMIQ capsules identical in appearance to placebo capsules.
|
280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body Fat
Time Frame: Change from baseline at 12 weeks
|
Whole body fat measured by both dual-energy X-ray absorptiometry (DXA) and skin fold thickness
|
Change from baseline at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anthropomorphic Measure I
Time Frame: Change from baseline after 4 weeks, after 8 weeks and after 12 weeks
|
Body weight
|
Change from baseline after 4 weeks, after 8 weeks and after 12 weeks
|
Anthropomorphic Measure II
Time Frame: Change from baseline at 12 weeks.
|
Waist/Hip circumference
|
Change from baseline at 12 weeks.
|
Metabolic Syndrome Measure I
Time Frame: Change from baseline at 12 weeks.
|
Triglycerides
|
Change from baseline at 12 weeks.
|
Metabolic Syndrome Measure II
Time Frame: Change from baseline at 12 weeks.
|
Total Cholesterol
|
Change from baseline at 12 weeks.
|
Metabolic Syndrome Measure III
Time Frame: Change from baseline at 12 weeks.
|
HDL
|
Change from baseline at 12 weeks.
|
Metabolic Syndrome Measure IV
Time Frame: Change from baseline at 12 weeks.
|
LDL
|
Change from baseline at 12 weeks.
|
Metabolic Syndrome Measure V
Time Frame: Change from baseline at 12 weeks.
|
Insulin
|
Change from baseline at 12 weeks.
|
Metabolic Syndrome Measure VI
Time Frame: Change from baseline at 12 weeks.
|
Adiponectin.
|
Change from baseline at 12 weeks.
|
Total protein
Time Frame: Change from baseline at 12 weeks.
|
Total protein measured in urine.
|
Change from baseline at 12 weeks.
|
Glucose
Time Frame: Change from baseline at 12 weeks.
|
Glucose measured in urine.
|
Change from baseline at 12 weeks.
|
Urobilinogen
Time Frame: Change from baseline at 12 weeks.
|
Urobilinogen measured in urine.
|
Change from baseline at 12 weeks.
|
Bilirubin
Time Frame: Change from baseline at 12 weeks.
|
Bilirubin measured in urine.
|
Change from baseline at 12 weeks.
|
Urine acidity
Time Frame: Change from baseline at 12 weeks.
|
Hydrogen ion concentration (pH) measured in urine.
|
Change from baseline at 12 weeks.
|
Ketones
Time Frame: Change from baseline at 12 weeks.
|
Ketones measured in urine.
|
Change from baseline at 12 weeks.
|
Occult Blood
Time Frame: Change from baseline at 12 weeks.
|
Occult blood count measured in urine.
|
Change from baseline at 12 weeks.
|
Resting Metabolic Rate
Time Frame: Change from baseline at 12 weeks.
|
Used to determine rate of calories burned per day.
|
Change from baseline at 12 weeks.
|
Nutritional Intake
Time Frame: Measures taken at baseline, week 6 and week 12.
|
Nutritional intake measures assessed via 3 sets of 3 24-hour dietary recalls by phone.
|
Measures taken at baseline, week 6 and week 12.
|
Three Factor Eating Questionnaire
Time Frame: Changes from baseline after 12 weeks.
|
Dietary restraint, disinhibition and hunger measured by Three Factor Eating questionnaire.
|
Changes from baseline after 12 weeks.
|
Food Cravings
Time Frame: Changes from baseline after 12 weeks.
|
Changes in food cravings assessed by Food Cravings-Trait questionnaire
|
Changes from baseline after 12 weeks.
|
Physical Activity
Time Frame: Changes from baseline at 4, 6 8 and 12 weeks.
|
Physical activity tracked and measured with the Stanford 7-Day Physical Activity Recall questionnaire.
|
Changes from baseline at 4, 6 8 and 12 weeks.
|
Mental Health
Time Frame: Change from screening to end of study (approximately 14 weeks)
|
Depression assessed by the Beck Depression Inventory.
|
Change from screening to end of study (approximately 14 weeks)
|
Heart Health
Time Frame: Change from baseline at 4 weeks.
|
Electrocardiogram (EKG) will be used to assess changes to heart rhythm.
|
Change from baseline at 4 weeks.
|
Liver Health Marker I
Time Frame: Change from baseline after 4 weeks, after 8 weeks and after 12 weeks.
|
Serum glutamic pyruvic transaminase (SGPT)
|
Change from baseline after 4 weeks, after 8 weeks and after 12 weeks.
|
Liver Health Marker II
Time Frame: Change from baseline after 4 weeks, after 8 weeks and after 12 weeks.
|
Serum glutamic oxaloacetic transaminase (SGOT).
|
Change from baseline after 4 weeks, after 8 weeks and after 12 weeks.
|
Kidney Health Measure I
Time Frame: Change from baseline after 4 weeks, after 8 weeks and after 12 weeks.
|
Blood urea nitrogen (BUN).
|
Change from baseline after 4 weeks, after 8 weeks and after 12 weeks.
|
Kidney Health Measure II
Time Frame: Change from baseline after 4 weeks, after 8 weeks and after 12 weeks.
|
Creatinine concentration.
|
Change from baseline after 4 weeks, after 8 weeks and after 12 weeks.
|
Kidney Health Measure III
Time Frame: Change from baseline after 4 weeks, after 8 weeks and after 12 weeks.
|
Glomerular filtration rate (GFR).
|
Change from baseline after 4 weeks, after 8 weeks and after 12 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mohsen Meydani, DVM, PhD, USDA Human Nutrition Research Center on Aging
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2885
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Children's Hospital Los AngelesUniversity of Southern California; Tufts Medical CenterRecruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Khyber Medical University PeshawarRecruitingObesity, OverweightPakistan
-
National Taiwan University HospitalCompleted
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Children's Hospital SrebrnjakBelupo; Podravka d.d.RecruitingBody Weight | Overweight and ObesityCroatia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States